Only 10% of tumor cells featuring mesenchymal properties harbored the ALK L1196M mutation, which means that 90% of these mesenchymal-type tumor cells had developed crizotinib resistance, while no ALK mutation was present [25]. Here, ALK is linked to neoplasm.